Passage Bio Stock Today
| PASG Stock | USD 0.67 0.08 11.12% |
Performance0 of 100
| Odds Of DistressOver 84
|
Passage Bio is trading at 0.6666 as of the 28th of November 2024. This is a 11.12 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.63. Passage Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Passage Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of February 2020 | Category Healthcare | Classification Health Care |
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 61.77 M outstanding shares of which 1.64 M shares are at this time shorted by private and institutional investors with about 6.61 trading days to cover. More on Passage Bio
Moving together with Passage Stock
| 0.75 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.67 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.68 | INKT | Mink Therapeutics | PairCorr |
Moving against Passage Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Passage Stock Highlights
| CEO President | William MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPassage Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Passage Bio's financial leverage. It provides some insight into what part of Passage Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Passage Bio (PASG) is traded on NASDAQ Exchange in USA. It is located in One Commerce Square, Philadelphia, PA, United States, 19103 and employs 58 people. Passage Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 46.39 M. Passage Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.77 M outstanding shares of which 1.64 M shares are at this time shorted by private and institutional investors with about 6.61 trading days to cover.
Passage Bio currently holds about 239.25 M in cash with (78.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Passage Bio Probability Of Bankruptcy
Ownership AllocationPassage Bio owns a total of 61.77 Million outstanding shares. Over half of Passage Bio's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Passage Ownership Details
Passage Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Fiduciary Trust Co | 2024-09-30 | 215 K | |
| Rbf Llc | 2024-06-30 | 142.8 K | |
| State Street Corp | 2024-06-30 | 123.9 K | |
| Two Sigma Investments Llc | 2024-09-30 | 98 K | |
| Marquette Asset Management Inc. | 2024-06-30 | 85.5 K | |
| Landscape Capital Management,llc | 2024-09-30 | 53.9 K | |
| Northern Trust Corp | 2024-09-30 | 40.3 K | |
| Engineers Gate Manager Lp | 2024-09-30 | 34.8 K | |
| Xtx Topco Ltd | 2024-09-30 | 29.6 K | |
| Orbimed Advisors, Llc | 2024-06-30 | 10.1 M | |
| Vestal Point Capital Lp | 2024-06-30 | 6.1 M |
Passage Bio Historical Income Statement
Passage Stock Against Markets
Passage Bio Corporate Management
| Sue Browne | Senior Development | Profile | |
| Simona King | CFO Sec | Profile | |
| JD Esq | General Secretary | Profile | |
| Gregory Fuest | Vice Marketing | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Kathleen Borthwick | Principal Finance | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.